JAN’S STORY – PARTICIPATING IN THE EXPERT CLINICAL TRIAL

We spoke with Jan about her breast cancer diagnosis, and her decision to participate in the EXPERT clinical trial.

Being Diagnosed with Breast Cancer

Jan White is a 75-year-old retired nurse who used to work in health, disability and aged care. Since she can remember, Jan has been having two yearly mammograms, and like any other appointment, she went in asymptomatic and expecting the ‘all clear’. However, the mammogram displayed a lump in her breast and she was diagnosed with breast cancer.

Jan is a participant in the EXPERT clinical trial, which aims to improve personalised use of radiation therapy in early breast cancer patients. We spoke with Jan about her diagnosis and her decision to participate in a clinical trial.

“My breast cancer diagnosis came about because even at my age I was still undertaking two yearly mammograms, which was my choice, and I went for one of my due mammograms, had no symptoms whatsoever and even after the mammogram none of the surgeons or nurses or anybody could feel the lump. So, without the mammogram it would have been undiagnosed.”

“So, I was lucky that I had continued going in for my mammograms, because in New Zealand we have to pay privately for them at my age, and otherwise I wouldn’t have been diagnosed. And because of that mammogram the tumor got picked up really early, which meant my risks were also reduced significantly, it turns out.”

“It was definitely a real surprise to me, not at all what I expected. I usually, like most women do, trot into our mammograms thinking, ‘oh yeah, I’ll have it done, so what?’ And then out came that diagnosis. I did have an inkling at the mammogram because the woman who was doing it went away to talk to a radiographer and then came back and wanted to take different shots.”

“So, because of my clinical background, I thought that something must be going on. But it was a shock, and something that I guess we all react to differently. I have a fairly ‘get on with it’ attitude to life, so did just get on with it. My husband doesn’t react very well to clinical things, so I almost brushed it over for him.”

“So, I was essentially managing it on my own, because I’d also made the decision that we wouldn’t involve family until I knew if I was having surgery, because I hadn’t seen a surgeon at that stage. But it turned out that we did tell our daughter and she came with me to the initial appointment with the surgeon and so they were all of course very supportive.”

“The boys we told what I was having the surgery for and that we were pretty sure it was early, and that there was no point flying into a blind panic about anything until we knew what the journey was going to be. And we decided not to tell the grandchildren despite their age, we just told them that Grandma was having some surgery, because three out of the four were all sitting exams at university and I didn’t want them getting emotionally upset about me and not doing well on their exams essentially.”

“Yeah, so since they found out they’ve all been fine, they’ve all adopted my attitude. I’ve been the strong one in the family, so I have always been inclined to brush over my own needs, which I continue to do with this. So I don’t think particularly the grandchildren realise the impact that this has had on me because I’ve hidden it from them, although the granddaughters might have picked up on it.”

Listen to the Podcast

Jan is a participant in the EXPERT clinical trial, which aims to improve personalised use of radiation therapy in early breast cancer patients. We spoke with Jan about her diagnosis and her decision to participate in a clinical trial.

How did you find out about the EXPERT Clinical Trial?

“When I came to my surgeon for the follow up after my surgery and to get the pathology reports, he went through all the pathology report with me and explained it all and, and that he felt that I was really lucky, the tumor was caught really early and I was really low risk. The biopsy came up with no spread, and he felt that it was a very early tumor.”

“He didn’t mention having radiotherapy to me and I remember sitting there thinking that he discussed radiotherapy at the initial appointment and so I asked him. So, he explained further about the level of risk that he thought I was and that he felt that it could be my decision whether I had radiotherapy or not and to go away and think about that. And I said, I can’t make that decision because everything I’ve been taught tells me to have radiotherapy, but the common sense of what I’m hearing tells me I don’t need it.”

“And he looked at me and he said, well I can’t tell you what to do Jan, I can only give you the information. And so, I said I’ll go and think about it. And as I went to leave, he said to me that there was this trial that I could participate in. Although I wasn’t compelled to, and then handed me over all the information, which is a huge amount of information, I think it’s about 15 pages.”

“So, he went through it briefly with me and said to go home, have a read, and think about it. And to let him know if I wanted to think about participating in the EXPERT trial, or if I wanted to do the radiotherapy or not. So, I went with the trial.”

“And he was very clear that even if I decided to go on the trial, and then decided partway through it that I was going to do radiotherapy, or if I was randomized not to have the new treatment, that I could pull out at any time. And that was big for me, knowing that I could decide this, but partway through if I really felt I needed to, I could pull out.”

“So, I went home, read all the information, and me being me, I researched the tests that the trial tells you that are undertaken in laboratories, and said yes. The reason for that is because thinking about it I decided I’d trust the science because I actually couldn’t make the decision on my own because of all my background and all my training. So, I decided that I would participate in the trial and trust the science and if I was randomised and didn’t have radiotherapy, that I would go with what the science was telling us for the trial.”

“I’m very committed to other people and my community. So the more I thought about it, the more I thought that if the science tells me I am low risk and can be randomised, that I actually owed it to future generations, and particularly older woman, to participate in the trial, which I understood would help guide whether, in fact, we needed essentially to have radiotherapy or not, when certain criteria are met with breast cancer.”

What has been involved in your treatment?

“It’s actually been really easy. There was another appointment with Dr Campbell, who happens to be the lead researcher, but also my surgeon. And appointments with Jenny, my research nurse. They went through line by line, all that information about the trial and the risks to me based on my pathology, and more importantly the ability to withdraw at any time.”

“They explained that if you scored under, I think it was 60. That neither they or I would know whether it was 60 or 15. So we wouldn’t know the percentage of risk for want of a better word. Just that it was deemed in the low-risk category, and I was therefore eligible for the trial. They also explained that if I was randomised, for the current standard of treatment that I would have radiotherapy plus the exemestane that Dr Campbell had prescribed.”

“And if I was randomised without traditional therapy then I would just have the tablets. And I was randomised without. So, I’m quite comfortable now with the decision I have made to trust the trial and trust the science. I’ve only been in the trial coming up to three months, so I’m about to have my first follow up.”

“And that was another thing that my daughter pointed out. She said to me that if I did go on the trial, I would have three monthly checkups for the next five years, including follow up with a nurse, and, you know, that’s just extra checking. So, breast exams and annual mammograms, and we have to have them anyway, but the trial will make sure I’m having it done regularly and having regular blood tests, checking bone density and all those sorts of things. They all get covered off nicely by someone else managing it, which will be nice.”

“So, I think that’s another bonus of the trial for women. Is that we get that extra follow up, that extra back up plan, those extra people that we can talk to if we need to. I think it’s important.”

“I’ve both nursed people, and I have friends and colleagues and I volunteer up at the Cancer Lodge here, so I see and have heard about some of the effects of radiotherapy. Not all women have side effects, like anything. Some of us get them, some of us don’t. But particularly older women appear to maybe have more side effects, or perhaps, if not side effects, have a greater impact on their lives from radiotherapy.”

“So, if they don’t need to go through that, and research can guide us on that, because you can’t just make the decision and pull it out of the air. It’s got to be research based; I think then that’s why we should do the trial.”

“If you’ve got the ability to support donating to any sort of research, but in this case, breast cancer, absolutely do it. I do a lot of talking in my big networks to people about the importance of donating to research and clinical trials and support research groups. So absolutely. If somebody asked me if I had somewhere they could suggest that they’d donate to, breast cancer research is on the list.”

What Would you say to Someone who was Thinking About Participating in a Clinical Trial?

“Absolutely do it, and I absolutely recommend it if you’ve weighed up the risks, you’ve been told all the information as I was. Absolutely. There’s lots of diseases that have been cured or managed because of research and people doing what the trial is doing.”

“It makes me feel good knowing that I might be helping future generations through participating in this research. It makes me feel as if my diagnosis has got some good out of it, if the trials and the research are able to alter the management of breast cancer, which is important for women. I mean even 10 or 15 years ago, women were dying of breast cancer. We’re often not now.”

GIVE TO RESEARCH HELPING WOMEN LIKE MADELAINE

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

LAURA’S STORY – PARTICIPATING IN THE DECRESCENDO TRIAL

We spoke with Laura about her breast cancer diagnosis, her decision to participate in the DECRESCENDO clinical trial, and her advice to other young women who have received a diagnosis.

Being Diagnosed with Breast Cancer

Laura Yang lives in Melbourne with her husband and her six-year-old daughter, where she enjoys listening to music, playing piano, and spending time with her loved ones. At the end of 2022, during a self-examination, Laura found a lump in her breast. The following week, she went to the doctor and was told that it was breast cancer.

Laura is a participant in the DECRESCENDO clinical trial, which is examining a new treatment approach which may have fewer side effects for people with early-stage HER2-positive breast cancer.

“I had a little lump in my breast, which I probably noticed about 10 years ago, when I was in China. So, I got it checked out and they said it was benign. They tested and they did a lumpectomy. And so, after that the doctor said to me that I just need to keep an eye on my breasts and do regular checks and things like that.”

“So, I do regular checks pretty much every year, even during COVID, and the result was all good. And then last year in September I went to the GP and then the GP said that my report from last year looked really good, and that I was able to just self-examine and keep doing what I was doing.”

“They said that I was doing the right thing and that I’m essentially all good. I was very happy. Then I came home I think probably, that was Friday, and then on the Sunday night I came home, and I was lying in bed, and I was actually feeling really grateful and happy. Like I was just thinking that my results are good, we have a little family, and we have a place to live, have a job and all of that.”

“And then I thought, the doctor said I need to self-examine. So, hang on, let me just do it now, which I never ever do but that’s what the GP told me to do. So, I did it and then I found this lump and then I said to my husband, I think I’ve found a lump here. And I said, do you want to feel it? And he said, no, I’m not the doctor just go straight back to the doctor.”

“I was a bit hesitant because I was just at the doctors last Friday, maybe I was just being paranoid or something like that? And he said, no, no, no, just go back and get it checked. So, I went back like the next week and she sent me to go and have an ultrasound. On my way back home from the ultrasound, the GP office rang me and said that the doctor would like to see me this afternoon, like right now, and to bring a support person.”

“And then I knew that it wasn’t going to be good if it’s that urgent and I need someone to support me. And then I found out it was breast cancer. I thought it was just a regular checkup, and also, I’m quite young and we have a young daughter. I have parents, a husband, and haven’t enjoyed life enough.”

“So, I think it’s just a shock to be honest, to myself that I’m so young and I’ve got it, and what does the future look like for me? What’s my purpose for life now? Like, am I going to die and when am I going to die or what will happen to my daughter?”

“I think we have been honest with her from day one. So, I just said to her, Mommy has a lump in my breast and it’s a bad one. So, the doctor is trying their best to get rid of it. And we didn’t mention cancer, so she didn’t know, but now she knows, and she tells everyone. She says my mama has short hair because she has breast cancer.”

“I think we’re lucky that she’s a very mature kid. She’s the only kid that we have, and she’s very smart, very cheeky too. I think she does worry about me, but it doesn’t seem to affect her a lot. So, we have a lot of people from school and our friends and family that support us and go her to school and her activities while I was having treatment. So, her routine is still there.”

“And also, I had my mum, when she got the news, she just flew from China straight away. No matter like how expensive the tickets were or what she was doing. So, she’s very lucky and I’m very grateful. So yeah, she still has her own routine. It changes but I think it’s good for her as her only child to be exposed to different people.”

“I think she does worry, but she wasn’t like crying every day or anything like that. But every time they bring like artworks and papers and cards home, all the cards would say like Mommy, I hope you feel better.”

Listen to the Podcast

Laura Yang lives in Melbourne with her husband and her six-year-old daughter, where she enjoys listening to music, playing piano, and spending time with her loved ones. At the end of 2022, during a self-examination, Laura found a lump in her breast. The following week, she went to the doctor and was told that it was breast cancer.

How did you find out about the DECRESCENDO Clinical Trial?

“So, my type is HER2-positive breast cancer, and all the way my experience with the medical team has been very positive. So, I think my oncologist introduced the clinical trial to me, and said that they have this trial and I am qualified, and I meet the criteria. And I am very open to trying new things. I just thought drug me up, whatever you need to do just make me better and get the cancer away. So, yeah, I’ve been on board from the beginning.”

“Everybody worries about chemotherapy, and because all the TV shows and things make it look horrible. So, when I started my treatment, they said that they will give me a gentler chemo, compared to normal chemo. And then they will give me this injection on my thigh, which is like an 8- to 10-minute-long injection, so instead of doing the IV, they do it in the thigh, and that’s three weekly. And I will be followed up by the same team of the doctors and then I have a trial nurse that always look after me.”

“And I’ve finished all my 12 rounds of chemo with no delaying, which I’m very proud of, and then I did my surgery, and I did about four weeks of radiation therapy. Now I am just on this thigh injection three weekly until I think the end of this year. So, all the intensive treatments are done.”

Do you feel well looked after?

“I do feel I am well looked after and they’re all lovely and beautiful. I think to me, it’s very important. I have this trial nurse to always guide me through or care for me, and she’s a lovely and very caring person, and is my point of contact as well.”

“So not just to organize my trial related things, but a lot more as well, she’s really helped me a lot during this process. And also by seeing only a couple of doctors on the trial, they know me, they keep an eye on me, and it’s always this couple of doctors, so I think it’s great.”

“You know, often with cancer itself, for me I had no symptoms at all. I felt the lump, luckily, but it doesn’t hurt, it doesn’t itch, I had no symptoms. So, it’s often the side effects that really gets people. You see on the TV or in movies, of course they over dramatise it, but it’s very harsh. It’s hard for human body. And I think I’m quite lucky that in this DECRESCENDO trial the chemo that I was given is one that is commonly given to seniors, like in their 80s.”

“So, if they can take it, you should be fine. So, I think that’s really encouraged me. Your mental preparation is very important if you’re thinking, okay, I’m going to face all the vomiting and all of the side effects, how is that going to affect my physical performance?”

“And so for me that was really reassuring and it really gave me hope that I didn’t have to suffer that much. And to be able to have sustainable treatment, because some side effects really put people off and also they just couldn’t take it physically and mentally.”

“I tried exercise, eating good food, everything to help me get through it. So my method is, because there are 12 runs, so 12 weeks, I just would take it week by week, and once I finish this week, I’m just focusing on getting well so I’m good to go for another week.”

“So just keep hitting that target and just achieve it. Now my hair is growing back and before, when I was bald it’s quite daunting and I think I was pretty brave because I just shaved it off because I just couldn’t take it, it was just everywhere. It was hard for me to clean and I didn’t want to see it.”

“It’s quite a hard time to deal with all that, you know, for a long time I didn’t want to go out or socialise with friends and family. Close friends and family that know your situation are good, and people are so nice, but they often ask you, how are you? And how can we help?”

“Normally when people ask you, how are you? You would say fine or good, but when I had to go through this and then when people asked me this simple question, how are you? And I just felt like, am I saying I’m good or I’m no good? Or am I going to details? It’s a simple question that people ask every day, but to me it’s actually quite a big question that I don’t know how to answer.”

What has been involved in your treatment?

“So, I think there were some hard times during the process, but now I think the hardest part was the side-effects. Mentally, I accepted it, and I did the hard part, but you know there were a lot of hurdles, like chemo, surgery, radiation, and you’re fighting with all the side effects, symptoms, fatigue, and also you just physically and mentally don’t feel well, and when you mentally feel down, you don’t want to do things.”

“But I think with the help of family and friends, and your community it becomes easier. I think I’m lucky that my result, apart from the bad news of the diagnosis, like my husband said that all of the news has been good.”

“So, when they got the tumour and there were no cancer cells in it, which means the chemo and the targeted therapy really worked well on me, and I’m proud that I don’t look like a cancer patient.”

“You know, even with breast cancer, there are so many different types and there are so many different treatments as well in terms of different treatment combinations, how many doses a person needs, you need a huge amount of research and time and energy and effort to be able to find the best way to help patients like us. So, I think it’s of course very important. Research is very important.”

What Would you say to Someone who was Thinking About Participating in a Clinical Trial?

“You will certainly be benefit from it. Of course, you know, do your research, talk with your medical professionals, talk with your family and friends. If you have questions or you’re not sure about something, just ask the professionals. You’ve not got anything to lose, only to gain.”

What are your hopes for the future?

“So, I just say to myself, in the future, or from now on, I just choose to be happy. And be present and live in the moment. It’s very hard for me to not worry about the future, but to really enjoy moments. I also want to be hopeful that with all the trials and with all the medical and science advancements that, who knows, there might be a cure.”

GIVE TO RESEARCH HELPING WOMEN LIKE MADELAINE

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

HOW TO USE RESPECTFUL LANGUAGE WHEN COMMUNICATING WITH BREAST CANCER PATIENTS

We spoke with Professor Fran Boyle AM about the importance of using respectful and inclusive language in breast cancer care so that patients can understand and make informed decisions about their treatment, and the common mistakes that can be made.

Communication plays a key role in a good relationship between a patient and their doctor. Research shows that after receiving bad news, anxiety, distress and even anger can be felt by patients. Understandably, patients often can’t process information that is said to them following bad news.

Professor Fran Boyle AM says health practitioners are responsible for what happens in that conversation and it’s a time when they need to show empathy rather than provide vast amounts of information. It’s important too that treatment teams check that a patient has understood what is being said to them. Health literacy can impact a patients understanding of their treatment and their disease, and can lead to greater distress.

So doctors have to remind themselves of what it is like to sit in the position of a patient and reading the memoirs of people who have been through a cancer experience can be very useful. Here is an excellent resource called the The Patient Doctor by Dr Ben Bravery. Dr Bravery became a doctor after he survived bowel cancer.

She says using the right language may be the difference between someone willing to participate in a clinical trial, which may save their life, or running away because it sounds too scary.

“Understanding what’s happening to you when you have breast cancer is absolutely critical. And so, it’s our responsibility as health professionals, not just to tell people stuff, but to actually have a conversation and a discussion that shows that the patient actually understands what we’re telling them.”

“So informed consent, isn’t just that you’ve told someone something, but that they’ve actually understood what it meant, and what the impact of that might be for them in a personal way, and they’ve had a chance to ask questions. So, if we are actually not using language well, then all of our informed consent is not valid, and patients have difficulty adjusting to what’s needed for treatment, but also then fears and concerns that don’t actually get addressed.”

“Research shows us that after receiving bad news, anxiety, distress, anger sometimes as well, is likely to wash over the patient and for at least the next few minutes. They’re probably not going to be processing terribly well anything you say to them. So that’s a good time for doctors to stop talking, and actually use ways of showing empathy, rather than trying to give information.”

“Patients often say, ‘after the event it was just a blur’ and ‘I have no idea what they said to me next’. And so that’s worth us remembering because we’re responsible for what happens in that conversation. One of the most common misconceptions in language is actually the use of the word positive.”

Listen to the Podcast

We spoke with Professor Boyle AM about the importance of using respectful and inclusive language in breast cancer care so that patients can understand and make informed decisions about their treatment.

What are some of the common words or phrases used in breast cancer treatment, that if used incorrectly can have a negative impact on a patient?

“So, in ordinary conversation, if I said to you that it’s a positive result, you’d think, you beauty, that’s great. We use the word positive though in a breast cancer sense to mean a positive lymph node is one that’s got cancer in it. A positive margin is a situation where the surgeon hasn’t been able to get all the cancer out. Hormone positive cancer might be a good thing to some people and a terrible thing to others. And HER2-positive breast cancer used to be a terrible thing. It isn’t anymore because we know how to treat that.”

“So that simple word positive is very confusing for patients. Is that good? Is that bad? And if you don’t explain then the patient goes away wondering how much trouble they are really in and they haven’t had the chance to clarify that.”

“Another good example that’s used by health professionals is the idea that if a treatment isn’t working for a patient, it’s common to hear people say in conferences, the patient failed first line treatment. Well actually the patient didn’t fail, the treatment failed. It didn’t produce the result that we wanted for that individual person. And it’s almost as if you’re trying to put the blame back on the patient for the fact that the treatment didn’t work. So clearly that’s not something that should be used in conversation with patients.”

Is the use of language something that is taught in the training of health professionals?

“We start communication skills training these days with our medical students very early in their first year of training. And the reminder that as they’re learning a new language, the language of medicine, they actually have to not lose the language they spoke before. So, they have to effectively become bilingual. To communicate with their other professional colleagues, they need one language and to communicate to patients they need another language.”

“And they may need, of course, an interpreter to help them with all of the other languages that our patients may have. So, just because you’ve focused on learning the jargon, don’t forget that ordinary words are going to be what you’re using in conversation with patients.”

“Clinical trials have eligibility criteria. Eligible is a word we use about bachelors. It’s something that’s great about someone. So, if you say to a patient, I’m sorry, you’re not eligible for a clinical trial, straight away they’re thinking that they’ve failed again. First of all, they’ve been diagnosed with cancer, and now they aren’t eligible for a trial, which is not a great place to be. So, what we should say instead is this trial is not suitable for you and let’s look again in the future because other opportunities may arise.”

“The word random is also something that we use when we’re talking about clinical trials. We randomize people. Well, random’s a word that in ordinary conversations with my children, they would think a random was a person who lived on the street, who was likely to be dangerous. And it’s not a great word when thinking ‘okay, I want to be randomised’. Another thing to think about is the analogy we use of tossing a coin, which can be described as randomisation. And if you happen to be a Seventh Day Adventist, anything that suggests gambling in any way at all is not going to encourage you to participate in a clinical trial.”

“So, thinking about the sorts of language we use may be the difference between someone being interested and willing to be involved in a clinical trial that could save their life and running away because it all sounds too scary.”

What has worked for you in communicating with patients?

“One of the things I’ve learnt is that you should always check that people have understood what you say. And that might be because they’re in a moment of strong emotion. It might be because their level of health literacy is not very high. Even simple words that describe parts of the body. The liver, the axilla, are things that people may not understand, especially if English is not their first language.”

“And so, checking that someone’s understood, that by axilla you mean the armpit, is actually very important. And patients often say to me, that was jargon, that was what you might say to one of your colleagues, but it’s not what I need to hear.”

“We do a lot of communication skills teaching with Oncology Professionals. They were actually the pioneers in this area in Australia, and all of our Oncology and Surgical Trainees come through a rigorous communication skills training program. And that’s run through the Pam McLean Centre at the University of Sydney.”

“And there are other providers around the country. What we do is we work with actors. They portray the role of the patient, and they give feedback to the person who’s participating. I didn’t get that. That didn’t feel like empathy. I didn’t understand what you meant. And that helps people to refine their skills. When there’s something new to learn in communication, a new trial that’s a little bit tricky to explain, or a new idea, then we might need to do some more training with people who are quite experienced, if it’s not something that they’ve been familiar with discussing.”

“So, it’s not something that stops when you leave medical school, it’s something that continues throughout your life.”

Are there any resources that you would recommend to patients or health professonals about this topic?

“In terms of resources to help sensitise people to how it feels to be a patient, reading memoirs of people who’ve been through a cancer experience can be very useful. There’s a great book by Ben Bravery called ‘The Patient Doctor’, and his experience of having colorectal cancer inspired him to become a medical student and now a Psychiatry Trainee and I would really recommend that.”

“Another great book is called ‘When Breath Becomes Air’ and it’s about a Neurosurgeon who has the experience of having lung cancer. And just seeing it from the other side is something that can help to open your eyes to what it’s like to be a patient and how many simple things are easy to misunderstand.”

HELP FUND WORLD-LEADING BREAST CANCER RESEARCH

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

THE CHALLENGE OF RECRUITING CALD COMMUNITIES TO CLINICAL TRIALS

Dr Rob McNeill explains the under representation of CALD populations in clinical trials research.

Dr Rob McNeill from the University of Auckland spoke at the Breast Cancer Trials 44th Annual Scientific Meeting about the challenges of recruiting CALD communities to clinical trials.

CALD stands for Culturally and Linguistically Diverse and there is an under representation of CALD patients involved in research.

Some of the challenges that Dr McNeill outlines includes:

  • communication and languages barriers
  • the location of trials in urban centres
  • clinical trial design and exclusion criteria, such as the ability to speak English and comorbidities
  • health systems that require a high level of health literacy
  • financial barriers such as the cost of travelling to hospitals, taking time off work, and paying for childcare during appointments
  • a lack of culturally appropriate resources and support

This results in inequity in the opportunity to participate in breast cancer clinical trials research and the consequent loss of potential benefits, such as access to new treatments that are not available yet. This also reduces the quality of trial data, which is not representative of the whole community.

An integrated plan of activities is required to improve diversity in clinical trial participation, which includes better engagement and inclusion of CALD communities to improve health outcomes in disadvantaged groups.

Dr McNeill was also a panel member on our Q&A topic: Breast Cancer in Māori, Pasifika and Indigenous Communities. To watch the Q&A or find out more, click here.

What is the Focus of Your Research?

“So, I’m interested in the experience of Indigenous and CALD patients in general in cancer services, and part of those cancer services is their involvement in clinical trials. And so, my journey into this has been through just doing general research around cancer patients experiences of their care.”

“And through that I’ve been hearing lots of stories through doing interviews and collecting data through surveys about not just the care they’re having for their kind of standard treatment, but also their experience of being recruited and being part of these clinical trials. And then more recently I’ve been involved in getting involved in some clinical trials here and specifically looking at patients experiences of being recruited and being part of those trials.”

“And my teaching background also gives me an interest in this because I teach on the social determinants of health. So, I’m specifically interested in the social factors that create barriers or enablers to patients’ engagement in services to keep themselves well, just in general. And how people’s resources, how their culture, how historical events might help us to understand why a particular culture might mistrust the health system, for example.”

“I think it’s important to understand the factors that are going to influence these populations willingness to be recruited into studies, and I think it’s important to understand what’s going to help them keep in those studies as well. Like, how are we going to maintain them in the trials once they are recruited? I mean, I think there’s two things to understand why we’ve got such low recruitment rates, or lower recruitment rates for indigenous and called patients in clinical trials.”

“Part of that is what I’d maybe refer to as clinical factors. So, we have exclusion criteria in trials. So, for example, excluding patients because they have comorbidities. And we know that particularly Indigenous populations, but also CALD populations tend to have greater levels of comorbidities.”

“They’re more likely to have other conditions that are going to exclude them from trials. We also know that clinicians have more of a reluctance, perhaps, I’m not sure reluctance is the right word, but are less likely to try to recruit CALD and Indigenous patients.”

“I mean, partly it might be just a perception that it’s going to take more time. It might be perhaps some unconscious bias that is meaning that they don’t even try to recruit CALD and Indigenous patients. And then on the patient side, and their family’s side of things is, you know, there’s a whole range of social factors like socioeconomic status.”

“There’s a whole lot of factors around economic and social resources. Patients are going to have financial barriers if they are from lower socioeconomic groups, and we know that Indigenous populations are much more likely to be in lower socioeconomic groups.”

“And so, you know there are also barriers to actually get to where the trials are. Barriers to being able to leave their family or children, like childcare responsibilities, transport. Even just getting access to a car to get to the hospital where they can be recruited to the trial. That becomes a barrier.”

“And then you’ve got cultural barriers. So, our health systems, both in Australia and New Zealand, they’ve been set up in a very Western kind of structure. That traditionally and historically hasn’t worked well for Indigenous populations. And it’s also very heavily English dominant, and so CALD populations, particularly those who have English not as a primary language are going to find it very difficult to engage with those services.”

“We’ve also got health literacy as being an issue for a whole lot of reasons, but we know that Indigenous and CALD populations are likely to have lower health literacy and I think that particularly plays out in their understanding of what the trials are about. This perhaps can influence their awareness of trials because of the language that gets used partly, and also, I think this is really a central part of the sort of research that I do, as it impacts a lot on their ability to navigate through the system.”

“Our health systems are complex and can be quite scary. So, for those populations who are less likely to understand how those systems work, it’s very difficult to access. And so that goes not just for the general health system, but also for navigating your way into a clinical trial.”

“Trust is another big issue, and we know that our histories in both Australia and New Zealand, is not a great history with both our Indigenous and CALD populations, but I think particularly with the Indigenous populations, things that have happened that have driven down the trust that those populations have not just with the health system, but with our governments in general.”

“And to overcome that is to try to overcome generations of mistrust. And I think that’s a really difficult thing to get around. And I think maybe the other thing that I haven’t talked about, and that’s particularly for the CALD populations, is language. Language is a big barrier. And a lot of trials still have exclusion criteria for people who are not fluent in English.”

“Is it ethical for us to do that? Like if you think about our health system, we can’t exclude people from receiving treatment in our health system because they can’t speak English. But for some reason we can exclude them from clinical trials that are potentially providing them with treatment because they don’t speak English. So, I think that’s a really difficult and interesting kind of conundrum for trialists because they’re not necessarily funded to try to overcome all of the language issues that they might have.”

“So, I mean two main outcomes is that these people, if they’re not part of these clinical trials then they are not getting access to some potentially good treatments for their disease, and so that’s a real negative for them. And on the researcher’s side of things, we’re not getting the best quality data that we can get about these new treatments because we’ve got parts of the population who are not represented. And I think that makes it difficult to generalise those results if we don’t have proper representation.”

Listen to the Podcast

Dr Rob McNeill is a senior lecturer at the University of Auckland, and we spoke to him about his research into the challenges of recruiting Indigenous and CALD patients to clinical trials.

Does There Need to be Trials Specific to different Ethnic Communities?

“So, whether we should have special clinical trials for Indigenous and CALD patients. I think that’s a tricky thing to answer. I think in some cases there might be opportunities to do that. I think in the cancer space it can be difficult because we’re often talking about quite small trials. And so, having even smaller trials that only include Indigenous and CALD patients could get quite difficult.”

“I’m not a trialist and so I don’t want to try to draw any conclusions about how difficult that might be. But it does seem difficult, but I think more importantly, it also might not be the best approach. I think the best approach is to make all trials work for the majority of the population, including important parts of our population, who are these Indigenous and CALD patients, who are the most vulnerable people that we’ve got in our community.”

“I think one of the most important things that we can do going forward with trying to improve the representation of CALD and Indigenous patients in these trials is to follow some of the recommendations that have come out recently from a project here that was funded through the Health Research Council, and involved a huge range of clinical trial people from here, not just cancer trial people, but trialists in general.”

“And their recommendations are about increasing the collaboration and involvement of Indigenous communities. But the same could apply to CALD involvement in all aspects of trials. So, from design all the way down to implementation, having more Indigenous and CALD health professionals who are there working with patients.”

“So, there are some significant workforce issues that we need to deal with. But also, making sure that the trials have meaningful collaboration and involvement from CALD and Indigenous peoples, like both experts, involving Indigenous and CALD researchers, but also involving consumers. I think consumer involvement is a big thing that we haven’t been doing as well as we should.”

“I think it’s been a bit of a ‘tick box’ kind of exercise up until recently, and I don’t want to sound like I’m more negative. The people I work with who are doing these things, they’re fantastic people and they are doing the absolute best that they can and they’re doing all sorts of things to try to make this better. But I still think we’ve got a long way to go, and a lot of iterations to try and get to the point where there is enough involvement of these communities in the actual trials themselves.”

“One of the ways that we can address these issues with the involvement of CALD and Indigenous patients is to just increase the representation of CALD and Indigenous health professionals who are working with these patients to recruit them, so that they’re seeing people that they identify with.”

What can be Done to Increase Awareness of Trial Participation in the Community but also among Health Professionals?

“I think we also need to raise awareness among health professionals and researchers and other groups about the sorts of things that they can do to try to reduce the barriers to involvement of these populations as well. It is important to define what we mean by CALD. I think a lot of our local audience in New Zealand probably wouldn’t understand the term CALD. But in Australia, it’s a very commonly used term to describe ‘Culturally and Linguistically Diverse Populations’. And quite honestly, when I first heard the term, I thought it would include Indigenous peoples as well, but it actually excludes Indigenous populations.”

“And in Australia the CALD population is about 30 percent of the population, so these are classified as people born outside of Australia, and it also includes some other populations as well. Here it’s much less easy to identify what proportion of our population are CALD, because we don’t really use the term that much, but it seems like it’s probably about the same proportion, but it’s quite different. Here our called populations are predominantly Pacific or Asian populations. I think in Australia it’s a much more diverse group of populations from a larger range of origins.”

“So, I think if you want to think about how big this problem is you need to think about how big the CALD population are. And in Australia and New Zealand, it seems like it’s about a third of the population. So, we’re not talking about small numbers here. It is a much bigger issue for CALD populations where English is not the primary language in the family, and that does bring us down to a smaller proportion than a third, but it’s still a significant proportion.”

“Another way that we can improve recruitment and engagement of Indigenous and CALD patients is by providing them with actual navigation through what is a very complicated system. And I’m talking about the health system within which these clinical trials are running. So, it’s difficult for patients to navigate normal services, but when you’re presented with the opportunity to get into a clinical trial, which involves potentially added complication and added nervousness about what’s going on.”

“I think some sort of navigation process, and some sort of navigation staff, is important to try to address that issue. And I think another important thing is to think about the economic barriers. I talk to patients all the time who, who struggle to get to their treatment because they’ve got childcare commitments.”

“I have patients who have refused treatment altogether because they don’t want to stop working because their family relies on them for their income. And so that’s been a really emotional thing for me to hear, that patients are actually either not having their treatment or stopping their treatment because of these financial barriers.”

“And I think the same is true for the clinical trial space, is that it does require extra visits to the hospital. It does require extra time for them to be engaged with the health system and with these research projects that, for a lot of people, is just completely unattainable. Even getting to appointments. So, we need to provide transport for people, provide them with taxi vouchers or some sort of transportation service, reimburse them for their time, provide them with vouchers for food for when they’re at the hospital, and for their visits.”

“There are so many things that we can do and there have been some fantastic campaigns. I saw one on the internet yesterday of a campaign in the US that had tried to raise awareness about these financial barriers and trying to get trialists to think about including these costs into their trials when they’re trying to obtain funding.”

HELP FUND WORLD-LEADING BREAST CANCER RESEARCH

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients
split-banner-image

ASCO 2023: BREAST CANCER RESEARCH SUMMARY

A summary of the key breast cancer research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

American Society of Clinical Oncology (ASCO 2023)

The American Society of Clinical Oncology (ASCO) annual meeting is one of the world’s largest and most renowned cancer conferences, bringing together leading cancer researchers, including those from Breast Cancer Trials, to discuss the latest advancements in treatments, clinical trials research and cancer care.

The following is a summary of the key breast cancer clinical trials research results presented at ASCO 2023.

NATALEE

Findings from the NATALEE trial were presented at ASCO and showed that adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival for patients with hormone-receptor positive, HER2-negative early-stage breast cancer.

Overall, the addition of ribociclib reduced the risk of disease recurrence by 25%. The invasive disease–free survival benefit seen in the ribociclib group was generally consistent across clinically relevant patient subgroups. Ribociclib also showed favourable outcomes in recurrence-free survival, and distant disease–free survival. More follow-up is needed to confirm the benefits.

EBCTCG Ovarian Suppression Meta-Analysis

A new meta-analysis of 25 studies dating back to 1948, including the SOFT and TEXT clinical trials conducted by Breast Cancer Trials, provides more evidence linking ovarian suppression/ablation in premenopausal women to reduce recurrence and improved survival in the long term, after early-stage breast cancer.

Suppressing ovarian function of women with breast cancer may improve outcomes by preventing estrogenic stimulation of any residual cancer, particularly for pre-menopausal women with estrogen receptor (ER)-positive tumours. This can be done by using an injection of medication such as goserelin or surgical removal of the ovaries.

Researchers found that for those who didn’t take tamoxifen – a standard treatment today – patients seemed to gain an especially large benefit. The randomized studies, which included 14,999 subjects, suggest that ovarian suppression/ablation can provide a substantial and persistent benefit for premenopausal women, reducing 15-year risk of recurrence and death from breast cancer without increasing mortality from other causes. Importantly, the benefits persisted for at least a decade after stopping treatment.

MonarchE Age Subgroup

Results from the MonarchE trial were presented at ASCO, where researchers reported efficacy and safety by age subgroups, to help guide management of older patients receiving adjuvant abemaciclib. Almost half of newly diagnosed breast cancers occur in women older than 65 years, who often have a higher incidence of comorbidities and increased risk for toxicities.

Adjuvant abemaciclib (a CDK4 & 6 inhibitor) combined with endocrine therapy, demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

In patients with high-risk early breast cancer, adjuvant abemaciclib plus endocrine therapy showed treatment benefit across age subgroups with a manageable safety profile. Older patients did have higher rates of adverse events and discontinuations, especially those older than 75 years, suggesting that more frequent surveillance with early intervention may be key to the management of these patients. This treatment has been recommended for funding in Australia by the PBAC, so is expected to become available in the near future.

Trastuzumab Deruxtecan Age Analysis

Trastuzumab Deruxtecan is approved for use in patients with HER2+ unresectable or metastatic breast cancer, after a prior anti-HER2-based regimen in the metastatic or neoadjuvant setting. Older patients with HER2+ metastatic breast cancer tend to have worse efficacy and safety outcomes, regardless of treatment. But their outcomes when treated with Trastuzumab Deruxtecan have not been thoroughly examined.

Researchers presented results at ASCO on age-specific (<65 vs ≥65 years) efficacy and pooled safety analyses of treatment with Trastuzumab Deruxtecan from the DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 clinical trials.

They found from this pooled analysis that treatment with Trastuzumab Deruxtecan has a favourable benefit-risk in patients older than 65 years. This treatment has shown remarkable activity and is expected to become available in Australia in the near future for patients with metastatic HER2+ breast cancer that has become resistant to initial therapy.

SONIA

Most international guidelines recommend upfront use of a CDK4/6 inhibitor in the first-line setting in HR-positive, HER2-negative advanced breast cancer, despite the prolonged toxicity and marked costs that come with extended treatment.

This is because several trials have shown that pairing a CDK4/6 inhibitor with endocrine therapy in the first-line setting improves both progression-free survival and overall survival. However, the combination also accomplishes this after initial treatment with endocrine monotherapy, and many patients can achieve lasting disease remission on first-line endocrine therapy alone.

The SONIA clinical trial compared the efficacy, safety, and cost-effectiveness of first- or second-line use of a CDK4/6 inhibitor when added to endocrine therapy in patients with HR-positive, HER2-negative advanced breast cancer, to provide better insight into the optimal sequencing strategy for these targeted agents in clinical practice.

Researchers found that while there were no marked differences in progression free survival or overall survival between the two cohorts, the time on treatment and the toxicity profiles for the different strategies painted a different picture. Patients who received a CDK4/6 inhibitor upfront remained on treatment for a median of 24.6 months, whereas patients who received it as second line remained on treatment for a median of 8.1 months—a difference of 16.5 months. This means that some patients may be able to have endocrine therapy alone as initial treatment, without impairing survival, with fewer side effects and costs.

SOFT/Text Analysis by Lauren Brown – PAM50

The landmark clinical trial called SOFT, in premenopausal breast cancer patients, revealed that the addition of ovarian function suppression (OFS) to adjuvant endocrine therapy with either tamoxifen (T+OFS) or exemestane (E+OFS), reduces the risk of recurrence compared with adjuvant tamoxifen alone. However, there are no biomarkers to aid decision-making about intensification of endocrine therapy with OFS.

The purpose of this secondary analysis of the SOFT trial by Australian researchers, was to assess the prognostic and predictive ability of PAM50 intrinsic subtypes and ROR scores in premenopausal women with HR+/HER2- breast cancer in the SOFT trial.

They found that subtype distribution significantly differed between very young vs young premenopausal women, with fewer luminal A and more luminal B and non-luminal tumours seen in the very young. The ROR score distribution also differed significantly: in node-negative patients there were significantly more ROR-high scores amongst very young compared to young women (36% vs 14%. Therefore, the ROR score can be considered to inform the prognosis of premenopausal patients with early-stage breast cancer.

X-7/7

The typical dose of oral capecitabine chemotherapy for metastatic breast cancer internationally is 1250 mg/m2 twice daily, administered in a 14-day on, 7-day off schedule, cycled every 21 days. However, this dose has been associated with poor tolerability and increased toxicities, often leading to treatment discontinuation. There has been a growing question regarding oral capecitabine’s optimal dosing and duration, aiming to minimise toxicity while maintaining efficacy.

The randomised clinical trial X-7/7 comparing the standard dose capecitabine (1250 mg/m2 twice daily 14 days on followed by 7 days off) with fixed-dose (1500 mg orally twice daily, 7 days on followed by 7 days off).

The study found that patients receiving a fixed-dose of capecitabine (lower than the current standard dose) on a regimen of 7 days on/7 days off experienced less toxicity and similar survival compared with those treated with the standard capecitabine therapy regimen. So fixed-dose 7/7 may be an alternative dosing option to minimise toxicity while maintaining outcomes in metastatic breast cancer.

BWEL

BWEL is a randomised study evaluating the impact of a telephone-based weight loss intervention in patients with stage II or III breast cancer who are overweight or obese. The study found that the intervention resulted in clinically significant weight loss in the patients receiving the intervention compared with a control group. Weight control is often challenging after a diagnosis and treatment for early-stage breast cancer, despite evidence that increased weight is associated with higher chance of cancer recurrence and other adverse outcomes.

A telephone-based weight loss intervention induced significant, clinically meaningful weight loss in patients with stage II/III breast cancer who are overweight or obese across demographic and tumour factors, but not across menopausal status or race/ethnicity. According to the study’s results, patients receiving the intervention lost an average of 4.8% (± 7.9%) of baseline body weight at 12 months vs 0.8% (± 6.4%) weight gain in the control group.

This is encouraging that it is possible to lose a meaningful amount of weight after a diagnosis of breast cancer with appropriate support. This in itself has a beneficial effect on cardiovascular outcomes and general wellbeing. Longer follow-up of the study will evaluate whether the intervention improves disease outcomes.

CANKADO

CANKADO is an app in development that supports patients during their treatment journey by providing a digital patient diary, web and app-based support, documentation of patient-reported outcomes and physician-patient interaction.

The PreCycle clinical trial evaluated the impact of CANKADO on quality of life in patients with metastatic breast cancer patients receiving palbociclib and an aromatase inhibitor, or palbociclib and fulvestrant.

The study found that patients receiving oral tumour therapy reported a significant benefit when using the interactive app. This app is not yet currently available, but these type of apps are on the horizon and hold great promise in supporting patients’ optimal quality of life.

 

YOUR DONATION CAN HELP UNCOVER BETTER TREATMENT OPTIONS

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

ASSESSING THE PARTICIPANT EXPERIENCE OF UNDERGOING BREAST MRI

As part of Breast Cancer Trials Clinical Fellowship program, Dr Julia Matheson will be assessing the participant experience of undergoing MRI, using patient reported outcome measures or PROMs.

As part of Breast Cancer Trials Clinical Fellowship program, Dr Julia Matheson will be assessing the participant experience of undergoing MRI, using patient reported outcome measures or PROMs. The research is an extension of the clinical trial called the Breast MRI Evaluation Study, which aims to establish when breast MRIs improve patient outcomes.

We asked Dr Matheson to explain the aim of this research and some of the barriers for accessing breast MRIs.

“My fellowship project is part of a much bigger clinical trial, which is looking at the role of MRI in women with newly diagnosed breast cancer. So currently the role of MRI in that patient group is incompletely defined. The aim of this study is to try and work out when MRI at the time of breast cancer diagnosis improves outcomes and when it does not.”

“At the moment, we know that up to a fifth of treating teams recommend a breast MRI for a patient with a new diagnosis of breast cancer, but there is quite a lot of variation in terms of whether it’s offered and whether it’s also available to patients. So hopefully this project will help to define the patients where it really makes a difference.”

“My component is looking at patient reported outcome measures. So those are measures that inform us of a patient’s health condition that’s reported directly by the patient. And in this study, we are using internationally recognised standardised questionnaires, and patients are being asked to complete these questionnaires at different points during the treatment pathway.”

Listen to the Podcast

We spoke with Associate Professor Redfern about the importance of addressing adverse breast cancer outcomes in Indigenous Australians.

How might MRI not being offered of being financially unattainable impact women?

“Because the exact role of MRI, so which patient group benefits, is unclear, I think it can be quite confusing for patients. There are a lot of different imaging modalities available.”

“Mammography is really the workhorse of breast cancer imaging, mammography and ultrasound are the more sensitive imaging modalities, like MRI. So, if patients are offered an MRI, they might be confused about why they’re being offered it and what it’s going to contribute to their treatment planning and outcomes.”

“It’s an additional test during a journey where they already have a lot of things happening, and some people can also find the MRI quite confronting. For patients who aren’t offered an MRI where they feel like it could be beneficial, it’s also challenging. So, MRI, the funding for it is quite tightly controlled based on Medicare rebates.”

“So in certain situations a clinician might think an MRI could be helpful, but there won’t be funding for it. And in those situations, not all patients will have the ability or the financial means to self-fund that test.”

“So we are hoping that this project provides more information and evidence so that MRI can be available to patients who are going to benefit, and that this component of their healthcare is equitable.”

Why has the role of breast MRI been a theme in breast cancer research?

“In breast cancer research we are always trying to improve outcomes for patients. Breast MRI is a more sensitive modality for looking at abnormalities within a breast. So particularly for patients who have a breast cancer that on MRI might be shown to be a lot more extensively than it looked on mammography, it can have a dramatic impact on the type of treatment and surgery that they’re offered.”

“And in some circumstances, it might mean that they don’t need to have subsequent treatments, or additional surgery. So, it helps to stage the patient to try and work out exactly how large the cancer is, and also if there’s any abnormalities in other areas of that breast or the breast on the other side, because those could also influence the type of treatment the patient gets and what they’re offered.”

“Patient reported outcome measures are any report of the status of a patient’s health condition that comes directly from the patient. So, in this study, we’re using a number of different measures and they’re looking at things like how MRI has influenced the patient’s preferences for the type of surgery they think they should have, their satisfaction with decision making at various time points through their treatment and follow up, the confidence they have in the treatment they’re receiving, and also if they have any regret about the treatment decisions that have been made.”

What are your hopes for the future?

“My hopes for the future of breast cancer research are that it continues to be an extremely dynamic and exciting field, that organizations like Breast Cancer Trials have a huge role in attracting great talent, ensuring that the research being done is of an extremely high standard and really world-class, and that those findings are being translated into better outcomes for patients.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

MARIA’S STORY

We spoke with Maria about her metastatic breast cancer diagnosis, her decision to participate in the TUGETHER clinical trial, and her advice to other women who have received a diagnosis.

Being Diagnosed with Advanced Breast Cancer

Maria Bodner is a retired nurse living in Victoria, Australia, with her husband. In 2013, Maria went in for her routine breast screen test. The following day, she received a phone call from one of the nurses asking her to come in so that they could review her results and Maria knew it was breast cancer.

Maria is a participant in the TUGETHER clinical trial, which aims to find out if adding tucatinib and pembrolizumab to the usual treatment given to people with advanced HER2-positive metastatic breast cancer slows down the growth of the cancer.

“My name is Maria Bodnar. I live in Maribyrnong, Victoria. I’m a retired nurse, and I have two children. I’ve been married for 48 years, and our son is 45 years old and married with four beautiful daughters. The oldest one is 15 and the youngest one is eight, going to be nine.”

“They live in Brisbane, so unfortunately, we don’t often see them as much as we would like to, especially during the COVID. That was a really hard time because we did facetime them often, but that’s not the same as having them around here and getting cuddles. So, they’re really beautiful. They’re coming in May again to visit us.”

“I also have a daughter who lives here locally. She’s unmarried, she’s 43. And I have a sister and a brother that are very supportive as well. And I’ve got a few very good friends that are always offering me an ear so I can complain if I want to.”

“Luckily I have some friends that are health professionals, so when I talk to them about something, they understand what I’m saying, you know, and I’ve got one very good friend who’s actually an oncologist. So, it’s sort of reassuring when she provides me with advice and all that, but often it’s just sort of having somebody who understands and sort of offering that ear to listen so that I can vent.”

“Other than that, I rest, I go to Peter MacCallum, I look after my husband, look after my house, socialize with my friends and family, I read sometimes but I find that my concentration is not the best lately. I like to watch movies, mainly on YouTube.”

“Occasionally when my husband and I are feeling okay, we’ll go for drives. We used to enjoy camping, but we can’t do it anymore. We go to church, we try to go regularly, and I pray sometimes, but not always, and that’s about it.”

Listen to the Podcast

Maria Bodner is a retired nurse living in Victoria, Australia, with her husband. In 2013, Maria went in for her routine breast screen test. The following day, she received a phone call from one of the nurses asking her to come in so that they could review her results and Maria knew it was breast cancer.

What Led up to Your Initial Breast Cancer Diagnosis?

“So, I was diagnosed in 2013 and the diagnosis was made after I had my routine BreastScreen test. When I had a phone call from BreastScreen, I was at work and they rang me up. They said to me ‘oh you need to come in, we have reviewed your scans’. I remember saying ‘sure let me have a look in my diary and see when I’m free’, and the lady said to me ‘Maria you don’t understand, we want you to come in tomorrow, we need to see you because you have cancer’. So, I went there, had a biopsy, had the surgery, and started chemotherapy and radiotherapy and I’ve kept on going for the last 10 years.”

“I was diagnosed with stage two, HER2-positive, estrogen-positive breast cancer in my right breast. I often say that I’m not really normal, because it didn’t really affect me the way some people are affected. Like a lot of people cry and they feel sorry. I sort of sat there and thought ‘oh well this is just my situation’, and it might be because I worked in the field in oncology that I didn’t cry as I’ve seen so much.”

“So, I thought to myself, I’m one of those women that has breast cancer, so what can you do about it now? And I remember the time when I was there talking to the surgeon and he said ‘Maria you need to have surgery’. So, I was booked in on the Saturday and I just started looking and reading about what I could do, how I could manage the treatment, if I should change my diet, all of those sorts of things.”

“I think my husband and my family took it hard. I think the way I informed my family possibly was a bit cruel because I invited them all over for dinner and told them together, as I didn’t want to go to everyone individually and say ‘hey I’ve got breast cancer’.”

“So, we had dinner and after dinner we had a talk, and that’s when I informed them. So, they were all very upset, and that’s what upset me. And I mean, I still can’t take people pitying me or crying over me. I’m much better off staying busy and working so I don’t think about it.”

“I think there are still a lot of people that see cancer and everything that’s associated with that. You know people often think that you have cancer so you’re dying, but it’s not always that way, you know, people live for many years with cancer, and they have good quality of life and all that. But I guess sometimes for some people it’s a bit hard to comprehend that and to understand, and I guess when it’s somebody in the family that you love, it makes it a bit harder.”

“I chose to remain positive, to take one day at a time and hope for the best. And it has worked for me so far.”

How did you find out about the TUGETHER Clinical Trial?

“Well, I was first introduced, or I was informed about the TUGETHER trial by my oncologist, and she thought that it would be a good way for me to go and provided me with information about the trial. I also did my own internet research, so I looked at the drugs, what they’re doing, and my oncologist thought that immunotherapy especially would help because that would work on my immune system, to help my body to fight the cancer.”

“So, I read all about that and I was bit concerned about side effects and we discussed all those side effects because they gave me the consent form with all the information. So, I read through it and I highlighted things that I didn’t know, so we could discussed it all. She explained everything to me, and I felt a lot happier about the treatment. So, I said ‘When can we start, I’m ready’.”

“I believe it’s running for two years, but if I’m doing okay and if it works on me, I can stay on the treatment further if it keeps cancer under control. That’s my understanding of it and what I read in the consent form.”

“So, I had a complication after surgery because I built up a lot of fluid and swelling. So, I was one of those patients that was a wearing draining tube for six weeks, because it kept on draining. So, when that healed, I started the first line of chemotherapy. So I had that for six cycles and finished that.”

“Then I started Tamoxifen and I continued with Herceptin because Ihad HER2-positive cancer. I had six weeks of radiotherapy that went well. I didn’t have major side effects, and I worked right through it because I worked at Footscray Hospital. Radiotherapy was at Western Private, so I would go during working hours. They would zap me and I would go back to work and continue business as usual.”

“I was on Tamoxifen for four years, so I was sort of in remission and I was very happy. And then one day at work I went for a dinner, and I bought myself salad in the cafeteria and the came in the office and I felt nauseous, and I thought that it was unusual because nausea is not something that bothers me.”

“So, I talked to a social worker and I said, ‘I had this salad in the canteen and I feel really funny’ and she said ‘oh Maria, you should know better than that you should never buy salad in the cafeteria’. But next morning I got up and I was nauseous again, and it kept getting worse and I thought this is not salad related.”

“So, I went to my GP and had an ultrasound and a blood test which showed that my liver enzymes were elevated. So, then I had an ultrasound of my liver, which showed multiple metastasis. And that sort of hit me because I sort of felt that maybe I wasn’t doing the right things because the cancer started spreading.”

“And again, I went to see my oncologist and had the liver biopsy and started again with the next lot of chemotherapy, which worked well. Then I started coughing. I went on an overseas trip, and I kept on coughing, just an irritating cough, but I didn’t know what was happening. So, I came back and went to see my doctor again at Western Health and she said to me that I should go to Peter MacCallum, because there was this new trial called DESTINY 2.”

“So, they made the referral for me and when I got there, they did a CT scan, pre-trial screening and all of that, and they found through the scan that I had lung metastasis and I had brain metastasis. So before starting DESTINY 2, I had to have radiotherapy to my frontal lobe and to my right temporal lobe for metastasis.”

“When that settled down, I started the DESTINY 2 trial, and I was on it for about 20 months. It worked well. I had a PET scan about eight months after I started the trial and it showed no evidence of cancer, so it was fantastic. Unfortunately, though that lasted only about one month or two months, and of course cancer came back.”

“So, I was off the DESTINY trial and started on standard treatment called TDM one, and I was on that for almost two years. Again, I did well, but then my cough got worse so I had a bronchoscopy, which showed that cancer on my lung has spread. That’s when Dr Loi thought that maybe I should try a different trial.

And when TUGETHER started I was accepted for that, so that was about four weeks ago, and I had my first cycle of the TUGETHER trial. At first it was tough, and the side effects were quite harsh, but I had my second cycle last Thursday and this time I’m doing a lot better.”

“They reduced my dose slightly because one of the drugs, capecitabine, affected my stomach a little bit too much. So, they reduced the dose by 20% and that seems to be good thing. So, yeah today is what five days since I had cycle two, and I’m doing well, so that’s great.”

Why did you Decide to Participate in a Clinical Trial?

“Well, I believe clinical trials are very good. I don’t think I would be here today if the women before me didn’t participate in the Herceptin trial, because I would’ve been dead years ago. So, I think it’s good because it’s here, it’s available. I don’t have to pay great amount of money for the new drugs. It’s my hope that it will help me, but also the results from the trial will help people after me because I’m here today because people went on a trial, and they were trialing those drugs which have now been approved for use.”

“They sort of found out what worked and what didn’t work, and how it all works. And with Peter MacCallum, regardless of whether I was on a clinical trial, I still had the most exceptional care. I have a fantastic oncologist and nursing staff. The contact I receive with the trial is very good, there’s possibly more support because we communicate regularly through email because I find it a lot easier.”

“But then always they tell me,’ I’m only phone call away’, so if I have a problem and I ring her up. Like after the first cycle when I rang up, the doctor rang me straight away the same afternoon. So I have continuity of care, which is very important to me because I’ve been seeing the same oncologist for last four years, and it’s sort of important to me that we build rapport.”

“I feel relaxed, and I feel safe. I know I’m in good care. My doctor releases all the scan results and my blood test and everything to me because I like to see everything, and for me it’s important to have all the facts to know what’s happening in my body.”

What Would you say to Someone who was Thinking About Participating in a Clinical Trial?

“Well, I think it’s important for me because it’s a new drug. Like I think this treatment that I’m getting, you know, it’s not available yet in Australia and if it was, I know it would cost quite a bit of money to do that. So, I’m privileged to have that drug that will potentially help me. And once it is proved on the trial that this drug is effective for people with breast cancer like mine, it’ll be approved, and it’ll be on PBS and it’ll be treatment available as a standard treatment for other people.”

“It’s important for me because it’s my life, but I guess working also in oncology for so many years and watching what women went through, I think new drugs and new treatments are prolonging people’s lives and improving quality of life and all that. And if we can continue to help that, it would be good. I used to always tell my patients when I was looking after them that you have to be here because there’s always a new drug.”

“I think the more new drugs we have and the more availability of the treatment, it’s better for the older cancer patients, not only breast cancer, but all other cancers. I’m usually positive person anyway. As I said earlier, when I was diagnosed, I sort of felt I had two options. Option one was maybe just give up and say, ‘okay, I’m dying that’s it’. Option two was to be positive, see what I can do, get the treatment that’s available, and just live one day at the time.”

“I think option two worked for me being positive because I think stress is a big contributor to cancer, so I sort to try not to be overstressed and overthink and panic about things like in two years’ time I might not be here because I’m here today and I’m like the boss.”

Why is Donating to Breast Cancer Research so Important?

“Well, I think with any treatment or trial or anything, financial money backup is very important, so supporting cancer research or supporting any sort of any research is very important. I mean, I was contacted recently by a fundraiser, and I can’t afford to give lots of money, but I have decided to give a little bit every month towards the research, and every little $5 or $10 donation counts.”

Do you have any Fears or Hopes for the Future?

“Fears? I have no fears. I have accepted my mortality. I would like to be around when my granddaughters grow up. I would like to see them growing up and I would like to enjoy life, but in terms of fears, I have none.”

“I know the day will come that I will be told there is not much else we can do for you, and that’s okay. I mean when I had my brain metastasis, I thought ‘that’s it’, and not because I thought ‘oh I’m not going to pull out through this one’ because I did, I had radiotherapy and a craniotomy, and I survived.”

“Somehow, I’ll keep on going. Or just enjoy as much as I can and travel when I can. Unfortunately, I can’t travel much with my husband because he’s unwell, and he depends on dialysis. So, I was talking yesterday with my sister, and we might go on the train trip to Darwin or something like that, just something for us to look forward to.”

GIVE TO RESEARCH HELPING WOMEN LIKE MADELAINE

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

INVESTIGATING THE IMPACT OF NOVEL BREAST CANCER TREATMENTS

Dr Julia Dixon-Douglas received a Breast Cancer Trials International Fellowship grant in 2023, and is focusing on Investigating the Impact of Novel Breast Cancer Treatments.

Breast Cancer Trials International Clinical Fellowship Support aims to financially assist promising junior researchers to gain international experience and connections. Dr Julia Dixon-Douglas has been awarded support in the first year of the program and is heading to France to study novel therapies for breast cancer.

Her research may help to improve our understanding of which patients will have the greatest benefit from these treatments and how they’re best administered to patients.

What is the focus of your research?

“I’m a Medical Oncologist at the Peter MacCallum Cancer Centre, and I work with the breast cancer unit. For the last two years I’ve been working as a clinical trials fellow, so mostly recruiting patients to clinical trials and looking after patients on clinical trials who are being treated with new therapies.”

“At the moment I am starting to delve a bit further into working in the lab. So rather than seeing patients and dealing with patients every day, I’m doing a bit of work in the lab to actually look at tumour and blood samples from patients under the microscope to understand which patients are benefiting from these treatments the most, and how we can use that information to better implement these treatments in the future.”

“Our response to new cancer treatments is really quite complicated and I guess determined by a number of different things. One component of it is how the tumor cells respond to the treatment that you’re giving. But another component, which sort of overlays with that, is how that interacts with the patient’s immune system and how that either allows or prevents the immune system from coming in and providing protection against cancer cells.”

“So, what this research is looking at is how the new treatments affect the tumor biology, both in terms of tumor cells, but also how they affect patients’ immune systems and how that information can be used to select patients for treatments better, or sequence treatments better, or combine treatments better.”

Listen to the Podcast

Listen to our conversation with Dr Julia Dixon-Douglas as she discusses her international fellowship grant with Breast Cancer Trials, and her research project looking into Novel Breast Cancer Treatments.

Why is going to France an important element of this research?

“Cancer research is really resource intensive, so it’s important that we share expertise and knowledge globally. So, an important part of that is international collaboration, which is why I’ve decided to go to the Institute Gustav Roussy, which is just outside Paris in France.”

“This is a leading European cancer centre that sees over 2000 new breast cancer patients a year. I’ll be working with a team who have world-leading expertise in translational research. So, looking at these patient samples of patients who’ve been on clinical trials with these new treatments, and they also run an active clinical trials unit, which is an amazing resource in terms of seeing patients on clinical trials and also collecting samples from patients on clinical trials.”

How will research from this project impact breast cancer treatments today?

“Every patient’s tumour is unique. At the moment, the way we treat breast cancer is pretty general, whilst we try and tailor treatments, it really is very general and many patients within a subtype of breast cancer will have similar treatments.”

“What this research is trying to do is identify biomarkers, so that we can implement these treatments in a more precise, individualized way so that patients can achieve the best outcomes with the least treatment, which will avoid unnecessary side effects and financial toxicity.”

“The overall aim is to uncover biomarkers to enable or to inform clinical trial development. So, coming up with new combinations of treatment, selecting patients for these new treatments, and developing clinical trials that involve selecting patients for new combinations of treatments, essentially to improve the chance of cure with fewer side effects.”

The role of novel therapies in treating breast cancer

In recent years, novel therapies including immune checkpoint inhibitors, antibody drug conjugates, and oral small molecule inhibitors, have been approved for the treatment of breast cancer. Can you explain what these are and their role in treating breast cancer?

“So, these are all examples of some of the new treatments that have been developed for the treatment of breast cancer, and there’s some really exciting research from clinical trials to show that they are effective.”

“But I think we’re really at the start line in terms of understanding how well they could work if they were implemented in a way that is optimized. And by that, I mean selecting the patients who are most likely to respond to those treatments, and understanding how they impact on the tumor biology and how that might inform how we could combine these treatments together.”

“So for example, immunotherapy is treatment that harnesses a patient’s immune system to help overcome cancer. Whereas a treatment like an antibody drug conjugate is a treatment that directly kills cancer cells. So, we need to learn how to be able to combine these treatments effectively so that not only are we killing cancer cells, but we’re also priming and harnessing the immune system to add long-term control to that as well.”

Why are novel therapies so important?

“I think this has the potential to affect all patients with breast cancer, by shifting their paradigm from a very general approach to cancer treatment, to a precise biomarker informed, directed approach to treating breast cancer, it has the potential to change how every patient with breast cancer is treated.”

“The treatment that we refer to when we think about traditional anti-cancer treatment is really chemotherapy. And chemotherapy does work well for some types of breast cancer, but it has a lot of side effects, including long-term side effects like heart problems, and the risk of secondary blood cancers. And we know that some patients, despite maximum chemotherapy, still will not be cured from their breast cancer.”

“So novel treatments that either target the machinery that tells a cancer cell to grow, or that harness the immune system to provide more longer-term control of cancer, are really the key to improving long-term cure rates.”

How will data from this study be used?

“This study will be looking at samples that have been taken from patients on clinical trials who’ve received these novel treatments on clinical trials. So, we’ll be looking at patient blood samples, to look at their circulating immune cells and we will also be looking at their tumour samples to look at tumour cells, and also immune cells that are embedded within the tumour.”

“We will be looking at how these immune cells, tumour cells, and genes change in response to treatment in patients who have both responded to the treatment, or have not responded to the treatment, or who have responded for a period of time, but then progressed, to understand these markers of response and resistance.”

Dr. Dixon-Douglas’ hopes for the future

“Breast cancer is a really diverse field. It’s really one of the few cancer types where we have the opportunity to use all of these different treatment modalities, and it’s a really heterogeneous field as well, meaning that every patient’s tumor is unique. So, what excites me about this research is moving from a very general treatment paradigm to a very specific, individualized precision medicine approach.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

SHAM’S STORY

We spoke with Sham about her metastatic breast cancer diagnosis, her decision to participate in the CAPTURE clinical trial, and her advice to other women who have received a diagnosis.

Being Diagnosed with Advanced Breast Cancer

Sham was born in Iraq in the Middle East but has lived in Melbourne with her parents and two children for the last seven years. In 2019, Sham was diagnosed with breast cancer after noticing some pain in her right breast while at work.

She is a participant in the CAPTURE clinical trial, which aims to identify women and men with hormone-receptor positive, metastatic breast cancer, who may benefit from a novel combination of drugs that may improve progression-free survival and offer a new treatment option. We spoke to Sham about her diagnosis and her decision to participate in a clinical trial.

“Yes, so it was 2019 just before COVID. I was at work, and I worked at Avis Budget Car Rental at the airport, and I just suddenly had a pain in my right breast. I thought ‘oh, it’s nothing’, but the pain kept coming back, and the next morning it happened again. So I had a day off next day, and then I thought, I’ll go and get it checked,” said Sham.

“So I had the ultrasound and biopsy and did all of the tests and things, including a mammogram, and they said that I do have breast cancer. I was shocked. I just couldn’t believe it. I didn’t know what to do or what to say. I just thought, how are my parents going to take it, you know I was just thinking of my mum and dad.”

“So I went to the hospital, everything was just urgent. My doctor called me the next day and they said, ‘you need to come in, we need to speak to you’. I told my sister, I didn’t tell my mum. So, when I told my sister I said the doctor just called and I need to go to the hospital.”

“While I was on the phone with the doctor, I was asking him what’s happening and I remember him saying, ‘I need to talk to you, you could have cancer’. I was like, wow okay. Then I went in and he said I’ll send you straight away to the hospital to do everything urgently so we can get on top of it as soon as we can. And then I started doing all the tests, they sent me to hospital, I did my other tests and everything.”

“I had a biopsy, and they booked me in for an operation. They said it’s just a very small cancer, it could be taken out. And then before the operation, it was on Friday morning, they called me and they said ‘we have to cancel the operation for Monday because it’s spread to your bones, to your spine, and to your lower back’. So straight away I started medication.”

“And now I’m on a trial. The people at the Peter MacCallum Cancer Centre they’re lovely and they look after me.”

Listen to the Podcast

Sham was born in Iraq in the Middle East but has lived in Melbourne with her parents and two children for the last seven years. In 2019, Sham was diagnosed with breast cancer after noticing some pain in her right breast while at work.

Tell us about your Treatment after you were Diagnosed

“First, I was diagnosed with breast cancer and then I started treatment with injections and tablets, and then I had 10 sessions of radiation and got better. Like every time I went to see the doctor and they said, ‘we can’t see the cancer  anymore, and you’re responding to the medication very well’. And then when I had it on my bones, they had to change the treatment.”

“They keep changing treatments. They changed it to chemotherapy tablets, so I’ve been taking them. And then after that they asked me if I wanted to go on a clinical trial, and if I’m interested in that. I was like, yeah, whatever helps. And why not? You know, to be honest I thought I’ll give it a go. I asked if many people go on it and what’s the outcome and things like that, and then I decided to give it a go.. That’s what the doctors suggested, and I know that they want to help me to get better.”

“When Julia told me about the trial and asked me if I wanted to do it and to think about it, I asked one of my colleagues who came with me, and she said ‘why not? If it’s going to help you’. And she said, ‘you know, there’s women on it who are doing well.’ So, I thought, yeah, I’ll give it a go.”

“The first dose they gave me had really bad side effects, you know, dry hands and dry feet so they just reduced the dosage down a bit more. So, the results are good. They keep saying it’s not getting worse, it’s stable. Sometimes I just get these pains when I’m tired, but it’s helped with other tablets and things. But they did say it’s nothing, there isn’t anything going on with your cancer, which is good.”

“When I first went to Peter MacCallum, I saw Dr James McCracken. He was amazing, he was really good. Every time I went, he used to give me the results and he made me feel really good and feel like I was really positive and kept getting stronger day by day with my results. The way they treat me is just nice, very good. I’m very happy.”

“The doctors at Peter MacCallum, and the nurses and everyone are amazing. I feel great. Like when I go to my appointments, they do take good care of me and tell me all about how I’m doing, and they explain things well. I feel comfortable when I’m there, and I feel good.”

Sham’s Hopes for the Future

“So, my hopes for the future are to get better and to be happy and healthy. And that this will never come back. My family and my children are very important to me, so I want to see them happy. That’s all I need. That’s my hope. And healthy, of course.”

“From day one, I was really upset, to be honest when they first told me that I was diagnosed with breast cancer. Straight away I thought about my parents, how I would tell them and how they were going to take it because my mum and dad can’t handle that.”

“I asked the doctors, I was like, ‘look I know I’ve got this, and I can fight it, I’m strong. It’s just my parents. How am I going to tell them, how are they going to take it? How are they going to handle it? And they told me just to say, ‘look I can do this, I can fight it’. And my children, I was really nervous and scared to tell them. I didn’t know how they were going to feel about this. But they knew I was strong when they saw me like that, especially my mum. Seeing her be so strong, made me feel like I’m stronger now.”

“I get stronger day by day, and I’m positive, always positive. I’ve got this and I’ll keep working and living my normal life and doing all the things I would normally.”

“To be honest, I feel lucky to be on the trial. I was worried that I wouldn’t be eligible for it, and I’m grateful to the other women who have been on the trial and participating in research. It’s because of them that so many women have gotten better today, and they’ve provided more hope with research through being on trials. It’s much better, because of the trials and the research.”

Why are Clinical Trials so Important?

“So being a part of clinical trial is very important, and every woman should look into it, and do her research and it really can help, now and in the future. A lot has changed from before. I know people that were diagnosed with breast cancer and had cancer in their ovaries and things like that, and they didn’t make it, but like they were just diagnosed for one, maybe two years and they’re gone which is very sad.”

“Nowadays, everything is just amazing. There are lots of options and every time the doctors tell me ‘Don’t worry if this doesn’t work, we have lots of options for you, we have this, we have that, we have other treatments that we can try’, which is really good.

GIVE TO HELP FIND NEW TREATMENTS FOR ADVANCED BREAST CANCER

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients

IMPROVING TREATMENTS THAT MAY HAVE LESS SIDE EFFECTS

Dr Adam Ofri received a 2023 Clinical Fellowship project with Breast Cancer Trials, and is focusing on two research projects: the ‘Targeted Axillary Dissection Based Study’ and ‘DCISionRT Based Study’.

As part of Breast Cancer Trials Clinical fellowship program, Dr Adam Ofri is working on two research projects focusing on de-escalation of treatment. His first study called the ‘Targeted Axillary Dissection Registry” will ascertain the safety and efficacy of targeted axillary dissection surgery (TAD), as an alternative to conventional axillary dissection, in patients who undergo neoadjuvant chemotherapy, which may produce less side effects.

His second study called the ‘The Australasian DCISionRT RCT’, aims to identify patients with DCIS who may be able to avoid unnecessary radiotherapy and the potential side effects.

Why is de-escalation of treatment such an important theme in breast cancer research?

“De-escalation in breast cancer has come about from our understanding of breast cancer pathophysiology. It used to be big operations with removal of the entire breast and cleaning out the armpit with the axillary dissections.”

“And over time we’ve realized that we can do less operating, less invasive procedures, but still maintain excellent outcomes for patients. And for me, the ability to offer the patient less invasive procedures means that they can have a better quality of life, and they have a lower risk of side effects, whilst knowing that I’m still providing them best care.”

Listen to the Podcast

Listen to our conversation with Dr Adam Ofri as he discusses his two research projects as part of the 2023 Breast Cancer Trials Clinical Fellowship Program.

Where does Australia sit in de-escalation of breast cancer treatment?

“I think Australia’s leading the way. They’re very eager to ensure that patients get tailored care. And a lot of the studies that are being conducted are to encourage best practice for patients. I think Australia’s had a good uptake with the targeted axillary dissection that has only really come out in the last 10 years. They’ve really been on board with trying to ensure that we can provide best practice without being excessive and really deescalating when appropriate.”

It’s a bit counterintuitive for a surgeon to say ‘we want to do less surgery’ and discussing radiotherapy, isn’t it? But throughout surgical training, you really learn about how to operate and when to operate. And when you get more senior, you start to learn about when not to operate, and that includes de-escalation, when to choose a less invasive operation – when you understand what the outcomes are, when you can appreciate if it’s going to have any impact on recurrence or disease-free survival or overall survival.”

“So, for me as a surgeon being able to tell a patient I don’t have to do something invasive, I can reduce your risk of a side effect or a sequalae, if you will, from a procedure, that makes me happy because less can be more, and I think that’s really true in surgery.”

What is Targeted Axillary Dissection?

“So Targeted Axillary Dissection is something that has been discussed in the last few years. For select breast cancer patients when they present, they’ll have a cancer in their breast, but they may also have it spread to their arm pit nodes.”

“Now, these type of patients in select cases could benefit from chemotherapy before surgery. Now with that change of practice, what we found is that we can in select cases, do less surgery in the armpit. So, if someone had turned up a decade or two ago with one or two nodes in their armpit, they would get what’s called an axillary clearance, which is to take away at least 10 nodes in the armpit.”

“This has risks associated with it. There are nerves, there’s vessels in the area, but also there’s a risk of developing lymphoedema, swelling in the arm. And that goes up to around 20-25% of cases. Now, a targeted auxiliary dissection is a way to evaluate the armpit nodes after chemotherapy and take away less nodes while still providing the same control of cancer in the armpit.”

“So, what it really is, is a targeted axillary dissection. And by evaluating how Australians are implementing this, how we are performing it, and how we manage the outcomes from it, I think we’ll be able to get data that’s more homogeneous rather than being all varied and subsequently allow us to evaluate it better.”

“And only with that strong, appropriate information can we then interpret it to figure out what we can now do beyond the TAD, and can we use the TAD and its results to do even less in the armpit without impacting patient outcomes.”

What methodology will this study use?

“So this study is really a registry and establishing the first registry in Australia where we capture high quality data about when people are choosing to do a TAD, how they do a TAD, and how they are managing the axilla after a TAD. The literature currently is a little bit varied with when people will do a TAD, how they do it and how they interpret it afterwards, which means that it’s really hard for us to know what’s best practice.”

“So, to be able to come up with what is best practice, we need to know what the practice is now, and we need to standardize what we’re doing if we want to evaluate it. And I think that’s one of the key limits that we currently have with determining where to go from here with a TAD because we don’t even have that appropriate data.”

“Some centres around the world are looking at how to de-escalate surgery, how to de-escalate management of the axilla after a TAD, and we just don’t know in Australia how we’re doing that currently.”

“So, by setting ourselves up to have a registry to collect the data properly, we can then evaluate that data, get a snapshot of what we’re doing, and from there we can build studies to evaluate TAD appropriately because we do a lot of surgery and we have a lot of breast cancer in Australia, unfortunately.”

“My hope is that by understanding how we do a TAD across Australia and discussing when we do it and how we manage it afterwards, we’ll be able to determine what may be better ways of doing it, whether we’ll be able to develop an Australian guideline or a recommendation regarding indications for a TAD, how to perform a TAD and subsequently what are the options of management after a TAD.”

What is your project ‘DCISionRT’ focusing on?

“DCISionRT is a really interesting test that’s been developed where you take breast tissue from  patients who have had DCIS (that is pre-cancer) and you test it to see how much benefit they would receive from radiotherapy, and it can quantify how high your chance of it coming back is. Because DCIS can come back again as DCIS, pre-cancer, but in 50% of the time when it comes back, it comes back as cancer.”

“So we need to determine should we give radiotherapy to all patients or are there some patients that may benefit in avoiding radiotherapy. And the reason it would be good to avoid radiotherapy if you can safely, is if unfortunately you get a recurrence you’ll be able to have what we call breast conservation therapy where we just cut out the cancer. We keep the majority of the breast, and we can give you radiotherapy.”

“If we’ve burned our bridge and used radiotherapy for a small DCIS, then if a patient develops breast cancer down the line, they’ll have to get a mastectomy. Because you can’t get radiotherapy twice to the breast. So, my thoughts are by appropriately using  DCISionRT, we can potentially avoid patients getting unnecessary radiotherapy, avoiding the side effects of radiotherapy and the impact on quality of life.

“And also on the other end, it can encourage us to give radiotherapy for some patients and motivate patients to have radiotherapy if they’ve got a more aggressive DCIS subtype. And some patients are scared of radiotherapy, and they don’t appreciate the benefit of it and being able to give them a number and say, this is how high your chances of getting a cancer or pre-cancer in the future can really help patients make an informed decision.”

What side effects can be associated with radiotherapy?

“So as a breast surgeon, we always have a little bit of an interesting discussion with our radiation oncologists, and we appreciate exactly what they do and the benefits. But from a breast surgeon point of view, radiotherapy can sometimes impact wound healing and it can change the appearance and the feel of the breast.”

“And sometimes if we’ve done a mastectomy and we’ve put in an implant, the radiotherapy can cause changing and scarring, which may need a patient to have another operation down the line to change things. So, radiotherapy is important because it reduces the risk of recurrence, but it can have those side effects.”

“It can also cause things down the line, albeit rarely because our radiation oncologists are very, very smart regarding how they’re doing their calculations and the delivery. But there are low chances of things like heart problems, lung problems and very rarely things like cancers forming.”

“So radiotherapy as great as it is, if we can de-escalate or avoid it, much like with axillary surgery, if we can provide tailored management to the patient and only give them the things that will benefit them, I think that everyone would agree that would be best practice.”

“My hope is if we can adequately perform a DCISionRT randomized control trial, and we show the benefits of it, I think this can impact every single person who has been diagnosed with DCIS. One in seven women are diagnosed by the age of 80 with a breast cancer, be it pre-cancer or invasive. And DCIS is more prevalent than invasive because we’re picking pre-cancerous up early. I think that this could have a great impact throughout all Australian and New Zealand patients.”

Is radiotherapy still the best standard of care?

“So that’s a good question, and that’s where I always explain to my patients, the evidence currently is if you have a lumpectomy that is only equal to having the breast off, also known as having a mastectomy, if you have radiotherapy, and that’s the standard line that I say.”

“In select situations, they may be able to avoid radiotherapy, in DCIS, and that’s where DCISionRT comes in.”

“Radiotherapy has been a game changer for breast cancer and it has allowed us to spare patients from losing their breasts. This has a significant improvement in the quality of life for patients, their mental health and also their sexual health as well.”

“By retaining as much of their own breast tissue, it can have so many good implications for patients, and we can only really do that with radiotherapy. So, to my patients, I always say it’s a highly advanced subspecialty, and radiation oncologists are researching consistently about how to employ the best radiotherapy techniques and modalities. I’d say to patients, it is one of the greatest advancements we’ve had in breast cancer.”

Dr. Adam Ofri’s Hopes for the Future

“All the research that we’ve done is always based off previous research. We’ve only moved to this place in breast cancer management and tailored and specialized breast cancer management because of all the hard work that other people have done. And it’s been through the tireless efforts of other researchers and academics that has led us to have the types of outcomes for breast cancer that we have.”

“The survivability is phenomenal in breast cancer, and that’s because of all the great advancements we’ve had.  I would hope that by providing quality research, I can help advance our level of knowledge of breast cancer and breast cancer management, and continue to help increase that rate of survivability, and have breast cancer be an unfortunate event, but not something that scares people anymore.”

Support Us

Help us to change lives through breast cancer clinical trials research

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients
split-banner-image

TREATMENT SIMPLIFIED – NO NEED TO START HORMONAL THERAPY ALONGSIDE CHEMOTHERAPY

The optimal timing of aromatase inhibitors around chemotherapy in the treatment of women with oestrogen receptor-positive, HER2-negative early breast cancer has previously been unknown.

Lead author of the recent ELIMINATE study, Associate Professor Nick Murray said that for the past 30 years chemotherapy and hormonal therapy – to reduce the amount of oestrogen – have generally been given sequentially in these women. This means the hormonal therapy was started later than it would be if given concurrently.

“Clinicians didn’t think about whether you should give them together or separately until there was one tamoxifen trial in the US in the 1990s in which it was given concurrently with chemotherapy,” he said. “In that trial, it was reported that the outcome for those women was worse. That influenced practice for many, many years. But when all the data for all trials [with tamoxifen] were put together it wasn’t shown to be worse, and there was a possibility it was actually better.”

Aromatase inhibitors, which work in a different way to tamoxifen, by lowering oestrogen concentrations in the body rather than blocking its action, were then developed. “Therapy with aromatase inhibitors had never been studied in the same way,” said Dr Murray, who is a medical oncologist at the Royal Adelaide Hospital Cancer Centre. “Should you give it at the same time as chemotherapy? We just didn’t know.”

To help answer this question, the ELIMINATE randomised trial was developed, in which 122 women from more than 20 cancer centres across Australia and New Zealand were evaluated. The women all had clinical stage 2 or 3 oestrogen receptor-positive, HER2-negative breast cancer, with an average tumour size of 45mm. Treatment involved surgery after chemotherapy (and endocrine therapy for 2/3 of the participants) had been given to reduce the size of their tumours.

The results showed there was no significant difference in shrinkage of the tumour by providing chemotherapy and aromatase inhibitors concurrently as opposed to sequentially. The standard of care remains chemotherapy for those whose tumour characteristics warrant it, followed by 5 or more years of endocrine therapy.

“It would have been nice if we’d seen a positive reaction to providing the treatments concurrently,” Associate Professor Murray says. “We certainly didn’t see any negative effects. But we’ve answered the question, cleared up an uncertainty and removed the need to do a much more expensive trial.”

A/Prof Murray says further work is being done to determine if there are some sub-groups of women for whom giving the treatments concurrently could be beneficial.

Publication:

  1. Murray, P. Francis, N. Zdenkowski, N. Wilcken, F. Boyle, V. Gebski, S.M. Tiley, L. Gilham, S-J. Dawson, S. Loi, A.D. Redfern, J. Lombard, A. Spillane, C. Shadbolt, H. Badger. Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial. Annals of Oncology. 2022, 33: S3. https://doi.org/10.1016/j.annonc.2022.03.107

 

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Associate Professor Nick Murray

Study Chair of the ELIMINATE trial Associate Professor Nick Murray.

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients
split-banner-image

SUPPRESSING OVARIAN FUNCTION INCREASES BREAST CANCER SURVIVAL IN HIGH-RISK PREMENOPAUSAL WOMEN

The latest analysis of data from two long-term international studies, the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT).

Up to 12 years from diagnosis, premenopausal women at higher risk of relapse following treatment for the most common form of breast cancer continue to benefit from 5 years of post-operative treatment suppressing ovarian function in combination with the drugs tamoxifen or exemestane.

That’s the general conclusion of two papers published in December 2022, following the latest analysis of data from two long-term international studies, the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT). Prior analysis was published providing results five years and eight years into the study.

“Twelve years is now long enough that you can start to see how much difference in survival you might get, particularly for some of the higher risk women,” says Professor Prue Francis of the Peter McCallum Cancer Centre.

Professor Francis, who is co-chair of SOFT and chaired the steering committee for both trials says the addition of ovarian suppression is providing at least a 4% improvement in overall survival at 12 years. “So that’s something that most women would consider potentially meaningful.”

Among premenopausal women with breast cancer, 80% have hormone-responsive breast cancer, where the hormone oestrogen can stimulate the growth of cancer cells.

To stop this from happening to any cancer cells that remain after the primary cancer has been removed, women may be treated with one or more hormone blocking drugs. These either prevent the uptake of oestrogen by cells (oestrogen blockers like tamoxifen), switch off the production of oestrogen in the ovaries (ovarian function suppression), or block oestrogen production in body fat (aromatase inhibitors such as exemestane).

SOFT and TEXT are independent, long-term, clinical trials involving thousands of women from all over the world, including 489 from Australia and New Zealand. These trials are investigating the effects of different hormone treatment combinations on survival and the recurrence of cancer in premenopausal women.

The research partly stemmed from the observation that women under 35 treated for hormone receptor positive breast cancer often had worse outcomes than women closer to menopause. One suggestion was that by placing younger women into a state of menopause, by suppressing their ovaries, might help prevent recurrence of the cancer.

The SOFT trial was established specifically to study if ovarian suppression was beneficial by testing two regimens. One added ovarian function suppression to the five years of either tamoxifen or exemestane prescribed for premenopausal women after surgery for breast cancer, and the other involved treatment with tamoxifen alone. The suppression could be permanent, with the ovaries removed via keyhole surgery, or temporary, using injectable drugs. Professor Francis says fewer than 10% of women, typically those close to menopause, opted for surgery.

The TEXT trial was set up to identify the difference between adding ovarian suppression to tamoxifen therapy and exemestane therapy. The protocols for adding ovarian function suppression were similar to those in SOFT. So, for those purposes, data from the two trials could be pooled, providing a larger sample for statistical analysis.

“At 12 years in SOFT, we can now see that some sub-groups of women at particularly high risk of recurrence seem to benefit from the more intense endocrine therapy with ovarian function suppression and exemestane,” Professor Francis says. They include women with larger tumours, who had chemotherapy before surgery. “Also, women under 35 look like they are getting a good survival benefit from ovarian suppression, and those with aggressive grade-3 tumours.”

On the other side of the coin, women with a lower risk of breast cancer have done well on average using tamoxifen alone without ovarian suppression. “This is a reassuring finding, that there are premenopausal women who don’t need chemotherapy and don’t need ovarian suppression. More than 95% in this group who did not receive chemotherapy are still alive.”

After 12 years the combined TEXT-SOFT analysis shows a continuation of trends that became apparent after five and eight years. Treatment with exemestane and ovarian suppression significantly improved disease-free survival and reduced distant metastases compared to tamoxifen and ovarian suppression, but not overall survival.

Additionally, the two oral drugs have different side-effect profiles, Professor Francis says. “Aromatase inhibitors (like exemestane) can have challenging side-effects. They certainly can cause more musculoskeletal complaints. They are harder on your sex life, and can cause more loss of bone density. Tamoxifen has side-effects, such as increasing the risk of blood clots, but these are not common.”

“What you need to understand in patients is to what extent a woman is willing to accept more side-effects to try and improve her breast cancer outcomes. Having a more intensified treatment may come at a physical cost. Women have different preferences.”

Publications:

  1. Prudence Francis, Gini Fleming, István Láng, Eva Ciruelos, Hervé Bonnefoi, Meritxell Bellet, Antonio Bernardo, Miguel Climent, Silvana Martino, Begoña Bermejo, Harold Burstein, Nancy Davidson, Charles Geyer Jr, Barbara Walley, James Ingle, Robert Coleman, Bettina Mller, Fanny Le Du, Sibylle Loibl, Eric P. Winer, Barbara Ruepp, Sherene Loi, Marco Colleoni, Alan Coates, Richard Gelber, Aron Goldhirsch, and Meredith M. Regan (2023) Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology 41 (7): 1370-1375. https://ascopubs.org/doi/10.1200/JCO.22.01065
  2. Olivia Pagani, Barbara Walley, Gini Fleming, Marco Colleoni, István Láng, Henry Gomez, Carlo Tondini, Harold Burstein, Matthew Goetz, Eva Ciruelos, Vered Stearns, Hervé Bonnefoi, Silvana Martino, Charles Geyer Jr, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric Winer, Barbara Ruepp, Sherene Loi, Alan Coates, Richard Gelber, Aron Goldhirsch, Meredith Regan and Prudence Francis (2023) Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Journal of Clinical Oncology 41 (7): 1376-1382. https://ascopubs.org/doi/abs/10.1200/JCO.22.01064

Support Us

Help us to change lives through breast cancer clinical trials research

profile image

Professor Prue Francis AM

Professor Prue Francis Chaired the International Steering Committee responsible for the SOFT and TEXT clinical trials and was the senior author of the publications.

Latest Articles

the global study helping breast cancer patients live longer
new immunotherapy approach offers hope for aggressive breast cancer patients